Roche Has Blockbusters In Its Pipeline – But Demurs On Predicting Hits
Flurry Of Pivotal Data In 2020
Biosimilars will take a bigger bite out of revenues in 2020 but Roche should score some hits from its broad pipeline.
Biosimilars will take a bigger bite out of revenues in 2020 but Roche should score some hits from its broad pipeline.